Overview
Company Does Not Provide H-1B Sponsorship
Aeolus Pharmaceuticals runs an online pharmacy that sells generic medications to customers worldwide through a large, frequently updated catalog. Customers browse the catalog, place orders for generics and related health products, and receive fast shipping with a focus on safe sourcing and quality assurance. It differs from competitors by prioritizing trust and safety in a counterfeit-prone market, combining domestic production with a professional team, and offering competitive prices plus fast delivery and bonuses. The goal is to help people maintain and restore their health by providing affordable, trustworthy access to quality generic medicines.
Work here?Claim your company
Simplify's take
What believers are saying
- Aeolus’s 2017 preclinical data showed survival gains after nerve-agent surrogate exposure.
- The company previously secured NIH CounterACT and HHS biodefense support.
- AEOL 10150 reached Phase 1 healthy-subject testing and ALS trials.
What critics are saying
- OTC Markets put AOLS on the Expert Market on 2026-11-07.
- Aeolus announced assignment for the benefit of creditors on 2018-03-23.
- The company discontinued all operations, leaving stockholders with no residual value.
What makes Aeolus Pharmaceuticals unique
- Aeolus’s only durable edge was AEOL 10150, a niche countermeasure platform.
- It won FDA Fast Track for acute radiation syndrome in 2017.
- Its biodefense focus targeted government-funded, scientifically demanding indications.
Help us improve and share your feedback! Did you find this helpful?